Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8085100 | 0.82 | SYK (0.71) | SYKMAPK8PIK3CGGSK3BCAMKK2 | |
| SCHEMBL27658519 | 0.75 | PDCD1 (0.50) | GSK3BHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL15569905 | 0.73 | SYK (0.87) | SYK | |
| SCHEMBL28762614 | 0.72 | SYK (0.67) | SYKMAPK8PIK3CGGSK3BCAMKK2 | |
| SCHEMBL15570607 | 0.71 | SYK (1.00) | SYK | |
| SCHEMBL6300562 | 0.71 | KMO (0.51) | HDAC1HDAC2 | |
| SCHEMBL19347497 | 0.70 | SYK (1.00) | SYKMAPK8PIK3CGGSK3BCAMKK2 | |
| SCHEMBL19347511 | 0.70 | SYK (1.00) | SYK | |
| SCHEMBL28093052 | 0.70 | CES1 (0.38) | — | |
| SCHEMBL6674350 | 0.69 | GSK3B (0.55) | SYKGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6040311-A | TREATING BONE DISORDERS FOR PREVENTING OSTEOPOROSIS OR INHIBITING BONE RESORPTION IN A MAMMAL; TREATING TUMOR GROWTH IN A MAMMAL | MERCK & CO., INC. (US) | 2000-03-21 | — | — | US | disclosed |